NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoclimab on Wednesday, September 7, 2022 at 8:00 AM ET.
The event will feature prepared remarks by company management and external key opinion leaders. A live question-and-answer session with company management will follow the formal presentations. To access the webcast, please register here.
An archived recording of the webcast will be available on Immunovant’s website for a limited time following its conclusion.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB…
The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest…
CHICAGO, IL / ACCESSWIRE / April 3, 2024 / The American College of Osteopathic Family…
Campaign underscores the urgency and need to support early career osteopathic family physicians.CHICAGO, IL /…
LAS VEGAS, NV / ACCESSWIRE / April 3, 2024 / Reveal Lasers, a burgeoning force…
Deeper integration unlocks powerful Weave features to improve patient experiencesLEHI, Utah--(BUSINESS WIRE)--Weave (NYSE: WEAV), a…